ALAR PHARMACEUTICALS INC.
Area: Government, Academia and Research Institutes
Booth No: N/A
Website: https://alarpharm.com/
Exhibitor Profile
Alar Pharm, a new drug development company, focuses on developing long-acting release injectables (LAIs) for treating central nervous system disorders & chronic diseases, including opioid use disorder, alcohol use disorder, chronic pain, treatment-resistant depression, and Parkinson's disease mainly. Our LAIs have distinctive characteristics such as low viscosity, small injection volume, and smooth drug release profile with fewer side effects, which provide better medication choices to patients.
Brands
ALA-1000, ALA-3000, ALA-4000
Exhibit Products
-
ALA-3000, a 1-month Ketamine released Injectable for treatment-resistant depression
-
ALA-1000, a 3-month Buprenorphine released injectable for treating opioid use disorder
Exhibitor Press Release
- Alar Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000 2022-05-13
Exhibitors you may be interested in
Highest Rated